NASDAQ · SWAV
Healthcare · Medical - Devices
$334.75
Down-$0.08 (-0.02%)
Updated Sep 11, 2026, 11:00 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
SWAV does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning SWAV.
SWAV research
Company profile and research snapshot.
ShockWave Medical, Inc., a medical device company, engages in developing and commercializing intravascular lithotripsy technology for the treatment of calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease (PAD); C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee PAD. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and sales managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 8, 2024 | Deutsche Bank | Hold | — |
| Apr 8, 2024 | Leerink Partners | Market Perform | — |
| Apr 8, 2024 | CL King | Neutral | — |
| Apr 8, 2024 | Morgan Stanley | Equal-Weight | — |
| Apr 5, 2024 | Canaccord Genuity | Hold | — |
No generated briefing is available yet.
Zacks Investment Research · May 7, 2024
Shockwave Medical's (SWAV) first-quarter results reflect robust revenue growth and gross margin expansion amid JNJ entering into a definitive agreement to acquire the company.
Zacks Investment Research · May 7, 2024
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks Investment Research · May 7, 2024
Although the revenue and EPS for Shockwave Medical (SWAV) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks Investment Research · May 6, 2024
Shockwave Medical (SWAV) delivered earnings and revenue surprises of 38.46% and 5.66%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SWAV.
No results
No recent SID articles mention SWAV.
